Roche Holding Company Profile (VTX:ROG)

About Roche Holding (VTX:ROG)

Roche Holding logoRoche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: VTX:ROG
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: CHF 97.02
  • 200 Day Moving Avg: CHF 83.62
  • Trailing P/E Ratio: 32.24
  • P/E Growth: 1.35
  • Dividend Yield: 1.0%

Frequently Asked Questions for Roche Holding (VTX:ROG)

What is Roche Holding's stock symbol?

Roche Holding trades on the VTX under the ticker symbol "ROG."

Where is Roche Holding's stock going? Where will Roche Holding's stock price be in 2017?

6 brokerages have issued 1-year price objectives for Roche Holding's shares. Their forecasts range from CHF 290 to CHF 335. On average, they expect Roche Holding's share price to reach CHF 312.50 in the next year. View Analyst Ratings for Roche Holding.

Who are some of Roche Holding's key competitors?

Analyst Ratings

Consensus Ratings for Roche Holding (VTX:ROG) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: CHF 312.50

Analysts' Ratings History for Roche Holding (VTX:ROG)
DateFirmActionRatingPrice TargetDetails
5/26/2017Goldman Sachs Group IncSet Price TargetBuyCHF 335View Rating Details
5/20/2017Morgan StanleySet Price TargetBuyCHF 290View Rating Details
5/20/2017Jefferies Group LLCSet Price TargetBuyCHF 305View Rating Details
5/20/2017JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
5/20/2017Barclays PLCSet Price TargetBuyCHF 320View Rating Details
11/3/2016Citigroup IncReiterated RatingBuyView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Roche Holding (VTX:ROG)
No earnings announcements for this company have been tracked by


Earnings Estimates for Roche Holding (VTX:ROG)

No earnings estimates for this company have been tracked by


Dividend History for Roche Holding (VTX:ROG)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Roche Holding (VTX:ROG)
No insider trades for this company have been tracked by


Headline Trends for Roche Holding (VTX:ROG)
Latest Headlines for Roche Holding (VTX:ROG)
DateHeadline logoDeadly brain infection in German MS patient prompts Roche investigation - Nasdaq - May 24 at 8:01 PM logoRogers to Participate in B. Riley & Co. Annual Investor Conference - May 24 at 9:42 AM logoRoche Holding Ltd. (ROG) Receives Consensus Rating of "Buy" from Analysts - May 22 at 8:38 AM logoRoche Holding Ltd. (ROG) PT Set at CHF 320 by Barclays PLC - May 21 at 11:46 PM logoRoche Holding Ltd. (ROG) Given a CHF 335 Price Target at Goldman Sachs Group Inc - May 21 at 11:46 PM logoRoche Holding's (ROG) "Buy" Rating Reaffirmed at JPMorgan Chase & Co. - May 21 at 11:08 PM logoRoche Holding Ltd. (ROG) Given a CHF 305 Price Target at Jefferies Group LLC - May 21 at 3:04 PM logoRoche Holding Ltd. (ROG) Given a CHF 290 Price Target by Morgan Stanley Analysts - May 21 at 11:20 AM logoImmunoGen drug moving ahead in single-agent, combination trials - Nasdaq - May 17 at 7:30 PM logoMerck says test shows Keytruda improves survival for bladder cancer patients - Nasdaq - May 17 at 7:30 PM logoRogers to Participate in Houlihan Lokey Global Industrial Conference - May 17 at 7:30 PM logoRegeneron profit misses estimates as Eylea sales growth slows - Nasdaq - May 5 at 8:09 AM logoETFs with exposure to Rogers Corp. : May 4, 2017 - May 4 at 7:50 PM logoRogers Corp. :ROG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 - May 3 at 7:23 PM logoU.S. FDA approves AstraZeneca's immunotherapy for bladder cancer - Nasdaq - May 2 at 9:45 AM logoRoche revenue rises 4% on strong sales - MarketWatch - April 27 at 8:01 PM logoWhy Rogers Corp. Soared Today - April 27 at 8:01 PM logoEMA panel recommends nod for Sanofi, Regeneron's arthritis drug - Nasdaq - April 23 at 9:08 AM logoRogers Corp. – Value Analysis (NYSE:ROG) : April 21, 2017 - April 21 at 7:22 PM logoRogers Corp. breached its 50 day moving average in a Bullish Manner : ROG-US : April 20, 2017 - April 20 at 8:30 AM logoRogers Schedules First Quarter 2017 Earnings Call for April 27 - April 19 at 7:32 PM logoRoche Holding Ltd. (ROG) Earns Buy Rating from JPMorgan Chase & Co. - April 18 at 10:37 AM logoBristol-Myers to license two drugs to Biogen, Roche - Nasdaq - April 15 at 8:27 AM logoJPMorgan Chase & Co. Reaffirms "Buy" Rating for Roche Holding Ltd. (ROG) - April 8 at 5:32 PM logoTrump's big pharma impact - April 7 at 12:20 PM logoRogers Corp. breached its 50 day moving average in a Bearish Manner : ROG-US : April 6, 2017 - April 7 at 12:20 PM logoRoche Holding's (ROG) "Buy" Rating Reaffirmed at Goldman Sachs Group Inc - March 31 at 7:17 AM logoRoche Holding Ltd. (ROG) Rating Reiterated by JPMorgan Chase & Co. - March 30 at 3:45 PM logoRoche Holding's (ROG) "Buy" Rating Reiterated at Goldman Sachs Group Inc - March 30 at 7:16 AM logoRoche Holding Ltd. (ROG) Stock Rating Reaffirmed by Goldman Sachs Group Inc - March 27 at 11:38 AM logoFDA approves Pfizer, German Merck immunotherapy for skin cancer - Nasdaq - March 25 at 7:12 PM logoMylan Settles With Genentech Over Patents for Breast Cancer Drug - - March 15 at 8:59 AM logoBUZZ-US STOCKS ON THE MOVE-Abercrombie, Kroger, PTC, Rada, Broadcom - Nasdaq - March 2 at 7:44 PM logoUPDATE 2-Roche trial finds new drug cocktail cuts breast cancer deaths - Nasdaq - March 2 at 8:12 AM logoNovartis cancer drug Zykadia gets FDA priority review - Nasdaq - February 23 at 8:20 AM logoEdited Transcript of ROG earnings conference call or presentation 21-Feb-17 2:00pm GMT - February 22 at 9:39 AM logoRogers (ROG) Shows Strength: Stock Adds 9.8% in Session - February 22 at 9:39 AM logoRogers Corporation Reports Fourth Quarter 2016 and Full Year Results - February 20 at 6:47 PM logoRogers Schedules Q4 & Full Year 2016 Earnings Call for Feb 21 - February 10 at 11:05 PM logoRoche said to consider options for Diabetes unit- Bloomberg - Nasdaq - February 1 at 3:44 AM logoBristol-Myers cuts 2017 outlook amid Opdivo competition - Reuters - January 27 at 2:24 AM logoEurope's oncologists back biosimilar versions of cancer drugs ... - Nasdaq - January 18 at 8:13 PM logoTweedy Browne Global Value Buys , , , Sells Hasbro Inc, , - Yahoo Finance - January 10 at 10:10 PM logoBallard Power (BLDP) Looks Good: Stock Moves 9.5% Higher - December 20 at 2:20 PM logoBlueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the … - November 14 at 7:32 PM logoRoche's Actemra successful in late-stage study in giant cell arteritis - November 14 at 7:32 PM logoRegeneron profit tops Street on lower costs - Reuters - November 4 at 6:46 PM logoROGERS CORP Files SEC form 10-Q, Quarterly Report - November 3 at 11:29 AM logo4:58 pm Rogers Corp beats by $0.13, beats on revs; guides Q4 EPS in-line - November 2 at 7:32 PM logoQ3 2016 Rogers Corp Earnings Release - After Market Close - November 2 at 10:44 AM


Social activity is not available for this stock.
This page was last updated on 5/26/2017 by Staff